CATANIA Coronary Stent System Makes TCT Debut
CeloNova BioSciences Inc.'s CATANIA Coronary Stent System features a NanoThin Polyzene-F surface treatment.
The CATANIA Coronary Stent System carries a CE Mark and is currently available for sale outside the U.S.
The CATANIA stent surface has been modified with highly lubricious Polyzene-F, a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation. This unique combination of stent and surface treatment reportedly effectively creates a new and different stent option, one that offers many of the clinical benefits of drug-eluting stents (DES), while addressing some of the significant ongoing concerns with DES technology such as potential for thrombosis and challenges associated with costly long-term dual anti-platelet therapy following treatment, including patient compliance, bleeding risks, drug intolerance and product cost, the company said.
According to CeloNova BioSciences, medical devices coated with Polyzene-F do not cause a negative reaction in the body when introduced, eliciting a normalized and positive bodily response. Polyzene(R)-F can be customized for the desired application and applied in a variety of ways including as a coating, extrusion, weaving, or electro-spinning ranging in thickness from less than 40 nanometers to more than 200 nanometers. The base substrate will be endowed with the properties of the polymer.
The rapid-exchange, cobalt-chromium CATANIA Coronary Stent System with NanoThin Polyzene-F is available in 60 sizes: in lengths from 8mm to 38mm, and in eight diameters from 2.0-4.0mm.
More like this
- CATANIA Coronary Stent System Makes TCT Debut
- CeloNova Commercialized Coronary Stent with NanoThin Polyzene-F Coating
- CATANIA Coronary Artery Stent Makes Live Case Debut During the Sociedad Venezolana de Cardiologia Intervencionista
- De Novo Coronary Lesions May Benefit from New Stent Treatment, Study Shows
- CeloNova BioSciences Inc